| Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management P Manu, L Dima, M Shulman, D Vancampfort, M De Hert, CU Correll Acta Psychiatrica Scandinavica 132 (2), 97-108, 2015 | 370 | 2015 |
| Buprenorphine treatment for opioid use disorder: an overview M Shulman, JM Wai, EV Nunes CNS drugs 33 (6), 567-580, 2019 | 262 | 2019 |
| Differences in aortic valve area measured with CT planimetry and echocardiography (continuity equation) are related to divergent estimates of left ventricular outflow tract area EJ Halpern, R Mallya, M Sewell, M Shulman, DR Zwas American Journal of Roentgenology 192 (6), 1668-1673, 2009 | 89 | 2009 |
| Thrombotic complications of treatment with antipsychotic drugs M Shulman, IJ Njoku, P Manu Minerva medica 104 (2), 175-184, 2013 | 56 | 2013 |
| Home-based outpatient telepsychiatry to improve adherence with treatment appointments: A pilot study M Shulman, M John, JM Kane Psychiatric Services 68 (7), 743-746, 2017 | 46 | 2017 |
| Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach M Shulman, A Miller, J Misher, A Tentler Journal of multidisciplinary healthcare, 489-501, 2014 | 46 | 2014 |
| Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse MG Greiner, M Shulman, TH Choo, J Scodes, M Pavlicova, ... Journal of Substance Abuse Treatment 131, 108447, 2021 | 31 | 2021 |
| Neurocognitive profiling of adult treatment seekers enrolled in a clinical trial of a web-delivered intervention for substance use disorders E Aharonovich, ANC Campbell, M Shulman, MC Hu, T Kyle, T Winhusen, ... Journal of addiction medicine 12 (2), 99-106, 2018 | 28 | 2018 |
| Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and … M Shulman, R Weiss, J Rotrosen, P Novo, E Costello, EV Nunes Addiction Science & Clinical Practice 16 (1), 15, 2021 | 27 | 2021 |
| The opioid use disorder core outcomes set (OUD–COS) for treatment research: findings from a Delphi consensus study NS Karnik, J Marsden, C McCluskey, RA Boley, KA Bradley, CI Campbell, ... Addiction 117 (9), 2438-2447, 2022 | 24 | 2022 |
| Life-threatening effects of antipsychotic drugs P Manu, RJ Flanagan, KJ Ronaldson Academic Press, 2016 | 21 | 2016 |
| Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi … NS Karnik, CI Campbell, ME Curtis, DA Fiellin, U Ghitza, K Hefner, YI Hser, ... Trials 22 (1), 102, 2021 | 18 | 2021 |
| Secondary analysis of pain outcomes in a large pragmatic randomized trial of buprenorphine/naloxone versus methadone for opioid use disorder M Shulman, SX Luo, ANC Campbell, J Scodes, M Pavlicova, A Broffman, ... Journal of addiction medicine 14 (5), e188-e194, 2020 | 16 | 2020 |
| Handbook of medicine in psychiatry P Manu, C Karlin-Zysman, E Grudnikoff American Psychiatric Pub, 2020 | 16 | 2020 |
| Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder KE Rudolph, NT Williams, ATS Goodwin, M Shulman, M Fishman, I Díaz, ... Drug and alcohol dependence 239, 109609, 2022 | 12 | 2022 |
| Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure M Shulman, TH Choo, J Scodes, M Pavlicova, J Wai, P Haenlein, ... Journal of substance abuse treatment 124, 108292, 2021 | 12 | 2021 |
| Co-occurring mood and substance use disorders JM Wai, M Shulman, EV Nunes, DS Hasin, RD Weiss Textbook of addiction treatment: international perspectives, 1297-1313, 2020 | 12 | 2020 |
| Cognitive functioning and treatment outcomes in a randomized controlled trial of internet‐delivered drug and alcohol treatment M Shulman, A Campbell, M Pavlicova, MC Hu, E Aharonovich, EV Nunes The American journal on addictions 27 (6), 509-515, 2018 | 12 | 2018 |
| Rapid initiation of injection naltrexone for opioid use disorder: a stepped-wedge cluster randomized clinical trial M Shulman, MG Greiner, HM Tafessu, O Opara, K Ohrtman, K Potter, ... JAMA Network Open 7 (5), e249744-e249744, 2024 | 11 | 2024 |
| Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables KE Rudolph, I Díaz, NS Hejazi, MJ van der Laan, SX Luo, M Shulman, ... Addiction 116 (8), 2094-2103, 2021 | 11 | 2021 |
Aimee CampbellColumbia University Irving Medical Center, Department of PsychiatryVerified email at cumc.columbia.edu
